Grifols (GRF) Stock Price, Fundamentals & Analysis

What GRF does

Grifols (GRF) is a Spanish healthcare company that researches, develops, produces, and markets plasma-derived medicines. It operates through four segments — Biopharma, Diagnostic, Bio Supplies, and Others — and supplies hemoderivatives for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology. It also provides diagnostic testing equipment and reagents, as well as biological products such as albumin and immunoglobulins to pharma and biotech companies. Grifols trades on the Bolsa de Madrid and is part of the IBEX 35.

Key numbers explained

• 9.59 EUR is the current share price, the latest trading value of one share of Grifols.
• The trailing P/E ratio of 14.5 shows how much investors pay per euro of the company's last 12 months of earnings; a lower number can suggest a cheaper valuation relative to recent earnings.
• The forward P/E ratio of 8.4 uses expected future earnings and is often read as a more optimistic valuation gauge than the trailing P/E.
• Dividend yield of 0.86% is the annual dividend payment expressed as a percentage of the share price, a common way to compare income returns across stocks.
• Ex-dividend date of 30 iun. 2026 is the date on or after which a buyer is no longer entitled to the next dividend payment.
• 35% of earnings paid out as dividends indicates the share of net income the company returns to shareholders, with the rest kept for reinvestment or other corporate purposes.
• Beta of 1.19 measures the stock's volatility relative to the broader market; a beta above 1 suggests it tends to move more than the market.
• Price-to-book of 1.18 compares the share price to the company's book value per share, a basic way to see whether the market values the company above or below its accounting net assets.

What to watch

• Revenue growth, which was -0.9% year over year on 7.42 mld. EUR trailing 12-month revenue, can signal changes in demand or pricing power.
• ProfitMargin of 6.1% and operatingMargin of 15.9% show how much of each euro of sales turns into net profit and operating profit, respectively.
• Debt-to-equity ratio of 117.2% indicates the company carries more debt than equity, which can affect financial risk and interest costs.
• ReturnOnEquity of 6.9% measures how effectively the company generates profit from shareholders' equity.
• NextEarningsDate of 28 iul. 2026 is the date when the company is scheduled to report its latest results, a common catalyst for price moves.
• Grifols operates in a sector that includes peers such as Alcon Inc (ALC) and Fisher & Paykel Healthcare (FPH), which investors may track for comparison.